Award
National Institute of Diabetes and Digestive and Kidney Diseases 5R01DK133871-03
Safety and Efficacy of Empagliflozin Main maintenance HD (SEED)
Recipient
New York University School of Medicine
Award Amount
$342,085.00
Ceiling
$342,085.00
Awarded
July 17, 2025
Identifier
5R01DK133871-03
This NIH-funded pilot clinical trial evaluates empagliflozin's safety and efficacy in patients starting hemodialysis, aiming to reduce cardiovascular risks and guide larger future studies.
Description
A phase II, randomized, placebo-controlled, parallel-group pilot clinical trial to evaluate the safety and efficacy of empagliflozin in adult patients initiating hemodialysis to inform a larger multi-center outcomes trial addressing cardiovascular disease and mortality in this population.